文献速递生殖医学

促性腺激素释放激素激动剂联合人绒毛膜促性腺激素(双触发)与单用人绒毛膜促性腺激素触发卵泡最终成熟的比较:一项双盲随机对照研究

GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study.
PubMed 文献 · Hum Reprod · 2020-01-01

该单中心双盲随机对照试验纳入155例正常反应患者,比较双触发与单用hCG触发对卵母细胞成熟及妊娠结局的影响。双触发组获卵数、MII卵母细胞数、囊胚总数及优质囊胚移植比例均显著高于hCG组,临床妊娠率和每移植活产率亦显著升高。

要点

  • 双触发较单用hCG显著增加获卵数、MII卵母细胞数及囊胚总数
  • 双触发组优质囊胚移植比例、临床妊娠率及每移植活产率均显著更高
  • 研究因中期分析结果提前终止招募,原文未报告局限性

核心结论

  • 与单用hCG触发相比,双触发用于卵泡最终成熟可增加获卵数、成熟卵母细胞数及囊胚数(总数和优质),并提高临床妊娠率和每移植活产率。

研究设计与样本

  • 单中心、随机对照、双盲临床试验,2016年5月至2018年6月开展,按意向性分析(ITT),共纳入155例正常反应患者。
  • 患者在招募50%后进行计划中期分析,基于中期分析的全部结局决定停止进一步招募。

主要发现

  • 双触发组与hCG组年龄(36岁 vs 35.3岁,P=NS)、BMI(24 kg/m2 vs 23.7 kg/m2)及AMH(20.1 pmol/l vs 22.4 pmol/l)具有可比性。
  • 基于ITT分析,双触发组较hCG组获卵数(11.1 vs 13.4,P=0.002)、MII卵母细胞数(8.6 vs 10.3,P=0.009)、囊胚总数(2.9 vs 3.9,P=0.01)及移植的优质囊胚比例(44.7% vs 64.9%,P=0.003)均显著更高。
  • 双触发组较hCG组临床妊娠率(24.3% vs 46.1%,OR 2.65(1.43-1.93),P=0.009)及每移植活产率(22% vs 36.2%,OR=1.98(1.05-3.75),P=0.03)均显著更高。

临床怎么用

  • 作者认为,双触发所观察到的增强反应若更广泛使用,可能带来更好的IVF结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does co-administration of GnRH agonist and Human chorionic gonadotropin (hCG; dual trigger) in IVF cycles improve the number of mature oocytes and pregnancy outcome compared to hCG alone? SUMMARY ANSWER: Using the dual trigger for final follicular maturation increases the number of oocytes, mature oocytes and number of blastocysts (total and top-quality) compared to triggering with hCG alone. WHAT IS KNOWN ALREADY: hCG is used at the end of controlled ovarian hyperstimulation as a surrogate LH surge to induce final oocyte maturation. Recently, based on retrospective studies, the co-administration of GnRH agonist and hCG for final oocyte maturation (dual trigger) has been suggested to improve IVF outcome and pregnancy rates. STUDY DESIGN, SIZE, DURATION: A single center, randomized controlled, double-blinded clinical trial between May 2016 and June 2018 analyzed by intention to treat (ITT). PARTICIPANTS/MATERIALS, SETTINGS, METHODS: One hundred and fifty-five normal responder patients were randomized either to receive hCG or dual trigger for final oocyte maturation. Data on patients age, BMI, AMH, number of oocytes retrieved, number of metaphase 2 (MII) oocytes, zygotes and blastocysts, clinical pregnancy rate and live birth rate were assessed and compared between the dual trigger group and the hCG group. We performed a planned interim analysis after the recruitment of 50% of the patients. Based on the totality of outcomes at the interim analysis we decided to discontinue further recruitment. MAIN RESULTS AND THE ROLE OF CHANCE: One hundred and fifty-five patients were included in the study. The age (36 years versus 35.3 years P = NS), BMI (24 kg/m2 versus 23.7 kg/m2) and the AMH (20.1 pmol/l versus 22.4 pmol/l) were comparable between the two groups. Based on ITT analysis, the number of eggs retrieved (11.1 versus 13.4, P = 0.002), the MII oocytes (8.6 versus 10.3, P = 0.009), total number of blastocysts (2.9 versus 3.9, P = 0.01) and top-quality blastocysts transferred (44.7% versus 64.9%; P = 0.003) were significantly higher in the dual trigger group compared to the hCG group. The clinical pregnancy rate (24.3% versus 46.1%, OR 2.65 (1.43-1.93), P = 0.009) and the live birth rate per transfer (22% versus 36.2%, OR= 1.98 (1.05-3.75), P = 0.03) were significantly higher in the dual trigger group compared to the hCG group. LIMITATIONS, REASONS FOR CAUTION: None. WIDER IMPLICATIONS OF THE FINDINGS: The enhanced response observed with the dual trigger might lead to better IVF outcomes were it used more widely. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by TRIO Fertility. There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT02703584. DATE OF TRIAL REGISTRATION: March 2016. DATE OF FIRST PATIENT'S ENROLLMENT: May 2016.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Haas J, Bassil R, Samara N, et al. GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study. Hum Reprod. 2020. PMID: 32563188. doi:10.1093/humrep/deaa107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。